Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SEASPINE HOLDINGS CORPORATION

(SPNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Update: SeaSpine Secures FDA 510(k) Clearance for 7D Percutaneous Spine Module -- Shares Jump in Pre-Market

07/08/2021 | 06:32am EDT


ę MT Newswires 2021
All news about SEASPINE HOLDINGS CORPORATION
09/22SeaSpine to Participate in the Cantor Virtual Global Healthcare Conference
GL
09/16SeaSpine to Host Analyst & Investor Event on September 30, 2021
GL
09/10ORTHOPEDIATRICS : SeaSpine Unit Enter Distribution Deal for 7D Flash Image Guidance System
MT
09/09SEASPINE : OrthoPediatrics Announces Entry into a Distribution Agreement with SeaSpine to ..
AQ
09/08SEASPINE : Starts Limited Commercial Launch of Mariner Adult Deformity System
MT
09/07SEASPINE : Announces Initial Launch of Mariner Adult Deformity System
AQ
09/07SeaSpine Holdings Corporation Announces Initial Launch of Mariner Adult Deformity Syste..
CI
08/13SEASPINE : Commences Limited Commercial Sale of WaveForm A Interbody System
MT
08/12SEASPINE : Announces Limited Commercial Launch of the WaveForm« A (ALIF) 3D-Printed Interb..
AQ
08/12SeaSpine Holdings Corporation Announces Limited Commercial Launch of the WaveForm« A 3D..
CI
More news
Analyst Recommendations on SEASPINE HOLDINGS CORPORATION
More recommendations
Financials (USD)
Sales 2021 202 M - -
Net income 2021 -34,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -14,7x
Yield 2021 -
Capitalization 573 M 573 M -
Capi. / Sales 2021 2,84x
Capi. / Sales 2022 2,52x
Nbr of Employees 421
Free-Float 84,7%
Chart SEASPINE HOLDINGS CORPORATION
Duration : Period :
SeaSpine Holdings Corporation Technical Analysis Chart | SPNE | US81255T1088 | MarketScreener
Technical analysis trends SEASPINE HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 15,75 $
Average target price 28,61 $
Spread / Average Target 81,6%
EPS Revisions
Managers and Directors
Keith C. Valentine President, Chief Executive Officer & Director
John J. Bostjancic Chief Financial Officer, Treasurer & Senior VP
Kirtley C. Stephenson Non-Executive Chairman
Chris Shen VP-Information Technology & Customer Experience
Frank Vizesi Vice President-Clinical Affairs
Sector and Competitors